newsfilter
← Latest News
Business Wire·

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods

ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, today announced its strong support for the U.S. Food and Drug Administration's (FDA) recent decision to phase out animal testing